NCT07483346招募中1 期
A Phase Ib Study to the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of IASO-782 in Patient With Systemic Lupus Erythematosus
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Number of participants with adverse events as assessed by CTCAE v6.0
研究概览
简要总结
his study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with SLE. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of SLE.
详细描述
This study is a multiple-dose escalation study in subjects with SLE. The study is designed to enroll subjects with SLE. This study will evaluate the safety and preliminary dose range of IASO-782 in subjects with SLE at the following dose levels:4mg/kg，6mg/kg and 10mg/kg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 75 years;
- •Clinically confirmed diagnosis of SLE before screening;
- •Currently receiving standard treatment regimens, including any single drug or combination of drugs;
- •Organ function or laboratory test is basically normal;
- •Subjects with potential fertility and their partners must use effective contraceptive measures for at least 2 weeks before the first dose of the study drug, throughout the study period, and for 6 months after the end of the study (or early termination of the study);
- •Females with potential fertility must have a negative pregnancy test during the Screening Phase;
- •Voluntarily participate in the study and sign the informed consent form.
排除标准
- •History of other primary malignant neoplasm within 5 years of screening;
- •A history of cardiac disease within the recent 3 months, including New York Heart Association (NYHA) Class III/IV congestive heart failure and cardiac arrhythmias requiring drug treatment;
- •Subjects with poorly controlled hypertension despite drug treatment;
- •A history of hypersensitivity to any component of the study drug or its excipients confirmed before screening;
- •Presence of active infection requiring intravenous drug treatment within 30 days before screening;
- •Pregnant or lactating females;
- •Participation in any other clinical trial within 28 days before randomization or within 5 half-lives of the study drug in the other trial (whichever is longer);
- •Previous treatment drugs have not been adequately washed out;
- •A previous history of any arterial or venous thrombosis (stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis or pulmonary embolism), or clinical symptoms and medical history suggesting thrombophilia; or any of the following: cardiac arrhythmias known to increase the risk of thrombotic events (e.g., atrial fibrillation), or a corrected QT interval (QTc) >450 msec in the subject; or a history of other coagulation abnormalities;
- •Confirmed diagnosis of severe lupus nephritis within 8 weeks before screening (defined as urine protein >6 g/24 hours or serum creatinine >2.5 mg/dL or 221 μmol/L), or requiring treatment with study-prohibited drugs, or having active nephritis requiring prednisone ≥100 mg/day or equivalent glucocorticoid for ≥14 days; active severe or unstable neuropsychiatric SLE, including but not limited to poorly controlled seizures, psychosis or acute confusional state, cerebrovascular accident, demyelinating syndrome, cranial nerve palsy, or evidence of active central nervous system vasculitis within 12 weeks before the screening visit;
- •Hepatitis B virus (HBV) infection during the Screening Phase (if HBsAg is positive, or HBsAg is negative but anti-HBc is positive, HBV-DNA testing is required, and the subject will be excluded if viral replication is indicated); positive anti-hepatitis C virus (HCV) antibody with positive peripheral blood HCV RNA; positive human immunodeficiency virus (HIV) antibody; positive specific treponema pallidum antibody with positive rapid plasma reagin test;
- •Tuberculosis (TB) infection: TB testing will be appropriately performed during screening according to local clinical practice. Subjects with active tuberculosis will be excluded, except for those with latent TB who are judged by the investigator to be eligible for the study;
- •A history of substance abuse or mental disorders;
- •Any other medical history or condition judged by the investigator to be unsuitable for study participation.
研究组 & 干预措施
Experimental group
Experimental
Drug:IASO-782 injection Dosage and Administration: single dose of IASO-782,4mg/kg ，6 mg/kg or 10 mg/kg , intravenous injection at day 1,day 8 and day15.
干预措施: IASO-782 injection (Drug)
Control group
Placebo Comparator
Drug:placebo Dosage and Administration: single dose of placebo, intravenous injection at day 1,day 8 and day 15.
干预措施: Placebo (Drug)
结局指标
主要结局
Number of participants with adverse events as assessed by CTCAE v6.0
时间窗: up to 25 weeks
The safety and tolerability of IASO-782 will be assessed primarily by summarizing treatment-emergent AEs and SAEs.
次要结局
未报告次要终点
研究者
研究点 (4)
Loading locations...
相似试验
招募中
1 期
A Phase Ia Clinical Trial of HW241045NCT07448194Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.56
已完成
1 期
An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005NCT07442149Alumis Inc135
招募中
1 期
A Study of B2065 in Patients With Acute Ischemic StrokeNCT07371624Tasly Pharmaceutical Group Co., Ltd54
招募中
1 期
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and the Food Effect of HSK55879 Tablets in Healthy Subjects.HealhtyNCT07521345Haisco Pharmaceutical Group Co., Ltd.46
尚未招募
1 期
Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2).Chronic Spontaneous Urticaria (CSU)Healthy VolunteersNCT07684560AlphaMol Science Ltd. (Shanghai)48